While biosimilars have gained traction in markets such as Europe and the United States, Canada’s progress has been cautious and comparatively slow. Despite the strong potential for cost savings and access expansion, a mix of regulatory, market, and policy challenges has hindered the domestic biosimilars market. The question is: why, and what can be done to change the trajectory?

The post-COVID, AI-driven world has reshaped the pharmaceutical industry in numerous ways, transforming processes, regulations, and, most of all, career pathways. What once worked in pharmaceutical hiring and operations has evolved into a rapidly changing digital...

It’s a question echoing through boardrooms, chat threads, and lab floors across the industry. The recent explosion of tools like ChatGPT, IBM Watson, Co-Pilot, and DeepSeek has sparked excitement and anxiety, depending on who you ask. But as artificial intelligence...

Last fall, the University of Toronto Mississauga (UTM) unveiled its state-of-the-art science building, one of North America’s most energy-efficient lab facilities. A key initiative within it, SpinUp, supports early-stage health and life sciences startups. In January 2025, we spoke with Raquel De Souza and Beverley Ayeni about UTM’s commitment to sustainability and innovation—an impact that will be recognized at the PSG Gala with the prestigious Sustainability Award.

Insights from PSG Leadership & Innovation Award winners, Roche Canada.